Table 1.

Patient characteristics

CharacteristicsNo. of patients (N = 236)Single pathway inhibition group (N = 160)Dual pathway inhibition group (N = 76)
Sex (male/female)98/13865/9333/45
Age, y
 Median58.960.558.1
 Range18–9026–9018–81
ECOG performance status
 0675017
 115910059
 210100
Ethnicity
 Caucasian18211567
 Hispanic46406
 African-American642
 Asian211
Tumor types (n ≥ 5)
 Colorectal564016
 Breast29227
 Soft tissue sarcoma241410
 Pancreatic17512
 Melanoma1679
 Neuroendocrine tumor1284
 Ovarian1174
 Prostate862
 Head and neck734
 Uterus endometrial651
 Renal cell660
 Genitourinary660
 Othera38317
No. of prior chemotherapy
 Median443
 Range1–101–101–8

NOTE: Single pathway inhibition group refers to patients who received either PI3K/AKT/mTOR or RAS/MEK/ERK pathway inhibitor as a single-agent therapy and dual pathway inhibition group refers to patients who received PI3K/AKT/mTOR pathway inhibitor and RAS/MEK/ERK pathway inhibitor as combination therapy.

Abbreviation: ECOG, Eastern Cooperative Oncology Group.

  • aOther includes lung, gastric, esophageal, and unknown primary.